The Translational Breast Cancer Research Consortium was well represented at the 2021 ASCO Annual Meeting. Presentations included:

Multi-center randomized study of pembrolizumab/carboplatin vs. carboplatin alone in patients with chest wall disease from breast cancer (TBCRC 044); Abstract # TPS1111

Pharmacokinetic analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis in HER2 positive breast cancer (TBCRC 049); Abstract #1044

A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer; Abstract #TPS1098